Thyrotoxicosis with pegylated interferon alfa-2b.
BACKGROUND: Despite adequate surgery, a diagnosis of stage III melanoma carries a high risk of relapse, and hence mortality. Interferon alfa is the only treatment that has currently been shown to alter the natural history of the disease, delaying relapse-free survival, particularly in patients with...
Main Authors: | Lowndes, SA, Asher, R, Middleton, MR |
---|---|
Format: | Journal article |
Language: | English |
Published: |
2010
|
Similar Items
-
Pityriasis Rosea Associated with Pegylated Interferon Alfa and Ribavirin Treatment in a Patient with Chronic Hepatitis C
by: Rahmet Güner, et al.
Published: (2013-06-01) -
Comparison of Pegylated Interferon Alfa Therapy in Combination with Tenofovir Alafenamide Fumarate or Tenofovir Disoproxil Fumarate for Treatment of Chronic Hepatitis B Patients
by: He J, et al.
Published: (2023-06-01) -
Real world experience with ropeginterferon alpha-2b (Besremi) in essential thrombocythaemia and polycythaemia vera following exposure to pegylated interferon alfa-2a (Pegasys)
by: Jumoke Okikiolu, et al.
Published: (2023-01-01) -
Interferon alfa-2b in the management of recurrent conjunctival papillomatosis
by: Manpreet Singh, et al.
Published: (2016-01-01) -
Pegylated Interferons and Their Use in Clinical Practice
by: Alpay AZAP, et al.
Published: (2003-12-01)